Creatine supplementation at high loading and low maintenance doses does not change how long cancer patients live compared to a placebo.
From A New Study Just Linked Creatine To Cancer · videoSee the scientific wording
Creatine supplementation, administered as a 20 g/day loading phase followed by a 2 g/day maintenance dose, does not significantly affect overall survival in cancer patients compared to placebo.
Unverified — no studies directly back this
We haven't found enough studies to verify this claim yet.
Score breakdown, mechanism chain, raw evidence, ideal studies needed
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Creatine supplementation at high loading and low maintenance doses does not change how long cancer patients live compared to a placebo.
Evidence from Studies
Last searched 2mo ago
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic review of randomized controlled trials examining creatine supplementation and survival in cancer patients
Comprehensive search of RCTs comparing creatine supplementation versus placebo in cancer patients, with overall survival as primary outcome, meta-analyzed with appropriate methodology.
Randomized controlled trial comparing creatine supplementation (20 g/day loading, 2 g/day maintenance) to placebo in cancer patients with overall survival as primary outcome
Double-blind, placebo-controlled RCT with cancer patients (e.g., advanced colorectal cancer), randomized to creatine (20 g/day for 5 days then 2 g/day) or matched placebo, followed for at least 2 years with overall survival as primary endpoint.
Prospective cohort study of creatine supplement use and survival in cancer patients
Prospective cohort of newly diagnosed cancer patients, documenting creatine use (dose, duration) and following for survival, with comprehensive data on cancer stage, treatment, and lifestyle factors.